Dicerna Pharmaceuticals, Inc. (DRNA) Reaches $12.94 After 8.00% Up Move; Last Week Allot Communications Ltd. (ALLT) Coverage

June 14, 2018 - By Louis Casey

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Logo

Among 4 analysts covering Allot Communications (NASDAQ:ALLT), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Allot Communications had 6 analyst reports since September 1, 2015 according to SRatingsIntel. Bank of America upgraded the stock to “Buy” rating in Wednesday, February 7 report. The rating was downgraded by Wunderlich on Tuesday, May 3 to “Hold”. Wunderlich upgraded Allot Communications Ltd. (NASDAQ:ALLT) on Thursday, October 29 to “Buy” rating. Jefferies maintained the stock with “Hold” rating in Thursday, September 7 report. As per Tuesday, September 1, the company rating was maintained by Oppenheimer. The stock has “Hold” rating by Oppenheimer on Tuesday, August 1. See Allot Communications Ltd. (NASDAQ:ALLT) latest ratings:

07/02/2018 Broker: Bank of America Rating: Buy New Target: $6.1 Upgrade

The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) is a huge mover today! The stock increased 3.69% or $0.46 during the last trading session, reaching $12.94. About 274,930 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 317.27% since June 14, 2017 and is uptrending. It has outperformed by 304.70% the S&P500. Some Historical DRNA News: ; 14/05/2018 – DICERNA PHARMACEUTICALS INC – BELIEVES THAT IT HAS SUFFICIENT CASH TO FUND EXECUTION OF ITS CURRENT CLINICAL AND OPERATING PLAN THROUGH 2019; 20/04/2018 – ALNYLAM REACHES SETTLEMENT PACT WITH DICERNA PHARMACEUTICALS; 03/04/2018 – Dicerna at HC Wainwright Global Biotechnology Conference Apr 10; 23/03/2018 – Report: Exploring Fundamental Drivers Behind Goldfield, Dicerna Pharmaceuticals, Deciphera Pharmaceuticals, WesBanco, Carolina; 20/04/2018 – DICERNA PHARMACEUTICALS – SETTLEMENT ALLOWS CO TO ADVANCE ALL KEY, PLANNED PIPELINE PROGRAMS; 20/04/2018 – Biotech companies Alnylam, Dicerna settle trade secrets case; 14/05/2018 – DICERNA PHARMACEUTICALS INC – QTRLY SHR LOSS $0.30; 20/04/2018 – Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam; 17/05/2018 – Dicerna Treatment Granted Orphan Drug Status by FDA; 20/04/2018 – DICERNA PHARMACEUTICALS INC – DICERNA WILL DISMISS ALL COUNTERCLAIMS ASSOCIATED WITH ALNYLAM’S TRADE SECRET MISAPPROPRIATION LITIGATIONThe move comes after 7 months positive chart setup for the $683.51M company. It was reported on Jun, 14 by Barchart.com. We have $13.98 PT which if reached, will make NASDAQ:DRNA worth $54.68 million more.

Since December 18, 2017, it had 1 buy, and 4 sales for $1.57 million activity. 10,000 shares were sold by Weissman James B, worth $150,000 on Wednesday, May 9. 9,669 shares valued at $145,035 were sold by Brown Bob D on Wednesday, May 9. On Monday, December 18 the insider Bain Capital Life Sciences Investors – LLC bought $2.00M.

Another recent and important Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news was published by Nasdaq.com which published an article titled: “Research Report Identifies Carolina Financial, Dicerna Pharmaceuticals, On Assignment, Digimarc, CIRCOR …” on May 18, 2018.

Investors sentiment decreased to 2.44 in 2018 Q1. Its down 0.56, from 3 in 2017Q4. It dropped, as 3 investors sold Dicerna Pharmaceuticals, Inc. shares while 13 reduced holdings. 24 funds opened positions while 15 raised stakes. 30.68 million shares or 5.45% more from 29.10 million shares in 2017Q4 were reported. First Manhattan reported 0.02% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Bridgeway Cap Management Inc owns 83,300 shares or 0.01% of their US portfolio. Blackrock holds 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 277,493 shares. Fmr Limited Liability Corp holds 0% or 1.71M shares. Bogle Mgmt Lp De reported 18,798 shares stake. Emerald Advisers Pa invested in 28,704 shares or 0.01% of the stock. Deutsche National Bank Ag reported 2,200 shares stake. Financial Bank Of New York Mellon Corporation holds 0% or 41,432 shares. Susquehanna Grp Limited Liability Partnership has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 86,291 shares. Quantitative Systematic Strategies Ltd Co reported 0.02% stake. Renaissance Tech Ltd Limited Liability Company owns 289,400 shares. Northern has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 59,384 shares. Spark Inv Management Limited Co has 145,000 shares for 0.09% of their portfolio. Birchview Cap Lp reported 45,000 shares or 0.28% of all its holdings. 125,000 were reported by 683 Capital Mgmt Lc.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $683.51 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

Analysts await Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to report earnings on August, 9. They expect $-0.42 earnings per share, up 63.48% or $0.73 from last year’s $-1.15 per share. After $-0.30 actual earnings per share reported by Dicerna Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 40.00% negative EPS growth.

Among 9 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Dicerna Pharmaceuticals had 25 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Buy” rating given on Tuesday, May 10 by Stifel Nicolaus. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Hold” rating by Chardan Capital Markets on Friday, August 11. As per Wednesday, April 11, the company rating was initiated by Cowen & Co. The firm has “Buy” rating by Stifel Nicolaus given on Friday, March 9. The rating was maintained by Cowen & Co with “Buy” on Tuesday, July 18. The rating was maintained by Chardan Capital Markets with “Neutral” on Thursday, June 30. The firm has “Buy” rating by H.C. Wainwright given on Friday, August 11. The firm earned “Buy” rating on Thursday, November 2 by Stifel Nicolaus. As per Friday, March 23, the company rating was downgraded by H.C. Wainwright. Stifel Nicolaus maintained Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) on Monday, August 10 with “Buy” rating.

Investors sentiment increased to 1.5 in Q1 2018. Its up 0.10, from 1.4 in 2017Q4. It improved, as 3 investors sold Allot Communications Ltd. shares while 7 reduced holdings. 7 funds opened positions while 8 raised stakes. 12.62 million shares or 1.42% more from 12.44 million shares in 2017Q4 were reported. Moreover, National Bank & Trust Of America Corporation De has 0% invested in Allot Communications Ltd. (NASDAQ:ALLT). Tower Ltd Com (Trc) holds 0% of its portfolio in Allot Communications Ltd. (NASDAQ:ALLT) for 815 shares. Fmr Limited Liability Corp has 1.95 million shares. 51,400 were reported by Spark Mngmt Ltd Company. Australia-based Macquarie Grp Inc Limited has invested 0% in Allot Communications Ltd. (NASDAQ:ALLT). Soros Fund Management has 0.44% invested in Allot Communications Ltd. (NASDAQ:ALLT). Deutsche Bancorp Ag invested 0% in Allot Communications Ltd. (NASDAQ:ALLT). Ancora Advsrs Ltd Liability Corp stated it has 0.03% in Allot Communications Ltd. (NASDAQ:ALLT). Vanguard Gru has 0% invested in Allot Communications Ltd. (NASDAQ:ALLT). Paw Corp has 4.52% invested in Allot Communications Ltd. (NASDAQ:ALLT). Oppenheimer & Company has invested 0% in Allot Communications Ltd. (NASDAQ:ALLT). Royal National Bank Of Canada, a Ontario – Canada-based fund reported 9,900 shares. Prentiss Smith & invested 0.03% in Allot Communications Ltd. (NASDAQ:ALLT). Geode Cap Limited Liability invested in 0% or 18,186 shares. Horrell Cap Management Incorporated invested 0.27% of its portfolio in Allot Communications Ltd. (NASDAQ:ALLT).

Allot Communications Ltd. provides visibility, intelligence, security, and monetization solutions that enable service providers and enterprises to protect and personalize the digital experience worldwide. The company has market cap of $179.36 million. The firm offers various platforms, including Allot Service Gateway 9500, Allot Service Gateway Tera, Allot Service Gateway, and Allot NetEnforcer for in-line deployment in traditional and virtualized network access infrastructure. It currently has negative earnings. It also provides subscriber management platforms, such as Allot TierManager, Allot QuotaManager, Allot ChargeSmart, and Allot Smart Engage Onboarding that drive centralized creation, provisioning, and pricing of subscriber services; and analytics solutions comprising Allot ClearSee Analytics and Allot ClearSee Data Source that analyze traffic data.

It closed at $5.34 lastly. It is down 6.79% since June 14, 2017 and is uptrending. It has underperformed by 5.78% the S&P500. Some Historical ALLT News: ; 17/04/2018 – ELETROPAULO TO ALLOT AT LEAST 80% OF OFFERING TO NEOENERGIA; 20/04/2018 – GRUPA KETY SA KTY.WA – AVIVA OFE AVIVA BZ WBK WANTS CO TO ALLOT 228.5 MLN ZLOTYS TO FY 2017 DIVIDEND; 16/03/2018 SANDHAR TECH TO ALLOT 4.63M SHRS TO ANCHOR INVESTORS; 17/04/2018 – IBERDROLA IBE.MC – ELETROPAULO WOULD ALLOT AT LEAST 80 % OF THE PRIMARY OFFERING TO NEOENERGIA

Another recent and important Allot Communications Ltd. (NASDAQ:ALLT) news was published by Prnewswire.com which published an article titled: “Allot Telco Security Trends Report Reveals CSP Security Services Prove Highly Effective in Protecting Consumers from …” on June 12, 2018.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>